EIP Pharma presented results from the AscenD-LB phase 2 clinical study of their oral drug, neflamapimod, in mild-to-moderate dementia with Lewy bodies. Results demonstrated that…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.